Real-World Effectiveness and Safety of Tucatinib, Trastuzumab, and Capecitabine in HER2-Positive Advanced Breast Cancer: A Multicenter Portuguese Study
Authors:
- Rita Quaresma FerreiraRita Quaresma Ferreira
- Carolina Brandão MonteiroCMCarolina Brandão Monteiro
- Ana Catarina DiasADAna Catarina Dias
- Francisca AbreuFAFrancisca Abreu
- Bogdana DarmitsBDBogdana Darmits
- Maria João OuraMOMaria João Oura
- Inês ÂngeloIÂInês Ângelo
- Joana CabralJCJoana Cabral
- Alice FigueiredoAFAlice Figueiredo
- Ricardo FerreiraRFRicardo Ferreira
- Diogo Alpuim CostaDCDiogo Alpuim Costa
- Maria Teresa MarquesMMMaria Teresa Marques
Open Access
- 17 June 2026
- journal article
- Published by Galenos Yayinevi in European Journal of Breast Health
- Vol. 22 (3) , 318-327
Abstract
Real-World Effectiveness and Safety of Tucatinib, Trastuzumab, and Capecitabine in HER2-Positive Advanced Breast Cancer: A Multicenter Portuguese Study - European Journal of Breast HealthKeywords
This publication has 18 references indexed in Scilit:
- Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesCA: A Cancer Journal for Clinicians, 2024
- Tucatinib Combination Treatment After Trastuzumab-Deruxtecan in Patients With ERBB2-Positive Metastatic Breast CancerJAMA Network Open, 2024
- A review of HER2 overexpression and somatic mutations in cancersCritical Reviews in Oncology/Hematology, 2023
- Targeting HER2+ Breast Cancer Brain Metastases: A Review of Brain-Directed HER2-Directed TherapiesCNS Drugs, 2022
- Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast CancerNew England Journal of Medicine, 2020
- Central Nervous System Metastasis in Patients with HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from SystHERsClinical Cancer Research, 2019
- Phase I Study of ONT-380, a HER2 Inhibitor, in Patients with HER2+-Advanced Solid Tumors, with an Expansion Cohort in HER2+ Metastatic Breast Cancer (MBC)Clinical Cancer Research, 2017
- HER2-positive breast cancerThe Lancet, 2017
- Impact of molecular subtypes on metastatic breast cancer patients: a SEER population-based studyScientific Reports, 2017
- Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Central Nervous System MetastasesJournal of Clinical Oncology, 2009